TP53-mutant acute myeloid leukemia/myelodysplastic neoplasms (AML/MDS) are distinct clinicogenomic entities characterized by chemotherapy resistance, high relapse rates, and poor survival. The gene discussed is TP53; the disease is acute myeloid leukemia.